Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
HRMY
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q2.23
-2%
0.56
vs 0.57
Q3.23
-21%
0.75
vs 0.95
Q4.23
-43%
0.45
vs 0.79
Q1.24
+40%
0.67
vs 0.48
Q2.24
-64%
0.2
vs 0.56
Q3.24
+5%
0.79
vs 0.75
Q4.24
+89%
0.85
vs 0.45
Q1.25
+16%
0.78
vs 0.67
Q2.25
+262%
0.72
vs 0.2
Q3.25
-1%
0.78
vs 0.79
Sales Growth
YoY
Current
Estimates
Q2.23
+25%
134.2M vs 107M
Q3.23
+37%
160.3M vs 117.2M
Q4.23
+31%
168.4M vs 128.3M
Q1.24
+30%
154.6M vs 119.1M
Q2.24
+29%
172.8M vs 134.2M
Q3.24
+16%
186M vs 160.3M
Q4.24
+20%
201.3M vs 168.4M
Q1.25
+19%
184.7M vs 154.6M
Q2.25
+18%
204.7M vs 172.8M
Q3.25
+17%
217.8M vs 186M
Return on Equity
QoQ
Q2.23
+7%
0.07
vs 0.07
Q3.23
+8%
0.08
vs 0.07
Q4.23
+6%
0.06
vs 0.08
Q1.24
+7%
0.07
vs 0.06
Q2.24
+2%
0.02
vs 0.07
Q3.24
+8%
0.08
vs 0.02
Q4.24
+8%
0.08
vs 0.08
Q1.25
+6%
0.06
vs 0.08
Institutionnal Ownership
QoQ
Q1.23
224
224
vs 244
-8%
Q2.23
214
214
vs 224
-4%
Q3.23
210
210
vs 214
-2%
Q4.23
225
225
vs 210
7%
Q1.24
212
212
vs 225
-6%
Q2.24
223
223
vs 212
5%
Q3.24
235
235
vs 223
5%
Q4.24
250
250
vs 235
6%
businesswire.com
8 hours ago
zacks.com
8 hours ago
zacks.com
9 hours ago
zacks.com
13 hours ago
seekingalpha.com
17 hours ago
Quote Panel
Key Metrics
Forecast
438%2026-Revenue
409%2026-EPS
392%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
48.00(40.47%)
Number of analyst
1
Last analyst upgrade/downgrade
UBS
initialisePrevious: Not converted
2024-09-09
Now: Buy
Citigroup
initialisePrevious: Not converted
2024-06-20
Now: Buy
Jefferies
upgradePrevious: Not converted
2022-10-14
Now: Buy
Zacks Investment Research
upgradePrevious: Not converted
2022-04-26
Now: Hold
Relative Strength
HRMY
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
NASDAQ
0.04Â ( 0.12%)
Relative Strenght
37
Volume Buzz
-50%
Earning Acce
No
Dist 52w H.
18%